Sort by
Refine Your Search
-
Listed
-
Category
-
Program
-
Field
-
: Monday 10 June 2024 Interview Date: To be confirmed Reference: 2719324CM Exploiting the innate and adaptive immune interface for effective cancer therapy (Cancer Research UK) We are seeking to recruit a
-
Reference: 2719324CM Exploiting the innate and adaptive immune interface for effective cancer therapy (Cancer Research UK) We are seeking to recruit a highly motivated and capable postdoctoral researcher
-
Europe's top cancer charity, Cancer Research UK, has combined with the University of Cambridge to fund the world class Cancer Research UK Cambridge Institute, situated on Addenbrooke's Biomedical
-
In 2013, Europe's top cancer charity, Cancer Research UK, combined with the University of Cambridge to fund the world class Cancer Research UK Cambridge Institute, situated on the Addenbrooke's
-
Developmental biology and Cancer research embedded in the University of Cambridge. It is supported by funding from the Wellcome Trust and Cancer Research UK, and provides an exceptional and stimulating
-
Developmental biology and Cancer research embedded in the University of Cambridge. It is supported by funding from the Wellcome Trust and Cancer Research UK, and provides an exceptional and stimulating
-
analysis. Why choose Cancer Research UK National Biomarker Centre? The Cancer Research UK National Biomarker Centre is a leading and highly specialised translational research centre within The University
-
interdisciplinary collaborators from non-mathematical backgrounds. Experience of multidisciplinary teamwork would be beneficial. Why choose Cancer Research UK National Biomarker Centre? The Cancer Research UK
-
neurodegenerative diseases. An independent organisation, its founding partners are the Medical Research Council (MRC), Cancer Research UK, Wellcome, UCL (University College London), Imperial College London and King’s
-
(MRC), Cancer Research UK, Wellcome, UCL (University College London), Imperial College London and King’s College London. The Crick was formed in 2015, and in 2016 it moved into a new state-of-the-art